[HTML][HTML] Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized …
E Mansour, FF Bueno, JC de Lima-Júnior, A Palma… - Trials, 2021 - Springer
Abstract Background SARS-CoV-2, the virus that causes COVID-19, enters the cells through
a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a …
a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a …
[HTML][HTML] Safety and outcomes associated with the pharmacological inhibition of the kinin–kallikrein system in severe COVID-19
E Mansour, AC Palma, RG Ulaf, LC Ribeiro… - Viruses, 2021 - mdpi.com
Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …
syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major …
[HTML][HTML] A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV …
P Malchair, A Otero, J Giol, X Solanich, T Carnaval… - Trials, 2022 - Springer
Background COVID-19 has quickly become a global pandemic with a substantial number of
deaths and is a considerable burden for healthcare systems worldwide. Although most …
deaths and is a considerable burden for healthcare systems worldwide. Although most …
Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
S Kumar, M Nikravesh, U Chukwuemeka… - Clinical …, 2022 - Wiley Online Library
Abstract Background & Aims Severe acute respiratory syndrome coronavirus 2 (SARS‐
CoV2) is a highly contagious virus that has infected 260 million individuals since December …
CoV2) is a highly contagious virus that has infected 260 million individuals since December …
[HTML][HTML] Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A …
P Urwyler, P Charitos, S Moser, IAFM Heijnen… - Trials, 2021 - Springer
Objectives Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target
inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the …
inhibitor of inflammatory cascades including the complement, the kinin-kallikrein and the …
Three-day Icatibant on top of Standard care in patients with Coronavirus disease 2019 pneumonia: A randomized, open-label, phase 2, proof-of-concept trial
P Malchair, J Giol, V García, O Rodríguez… - Clinical Infectious …, 2023 - academic.oup.com
Background We aimed to evaluate icatibant, a competitive antagonist of the bradykinin B2
receptors, for the treatment of inpatients with coronavirus disease 2019 (COVID-19) …
receptors, for the treatment of inpatients with coronavirus disease 2019 (COVID-19) …
[HTML][HTML] Response to recent commentaries regarding the involvement of angiotensin‐converting enzyme 2 (ACE2) and renin‐angiotensin system blockers in SARS …
RC Speth - Drug development research, 2020 - ncbi.nlm.nih.gov
2/27/20 An open label, randomized, controlled, pilot clinical study in patients with COVID-19,
to obtain preliminary biologic, physiologic, and clinical data in patients with COVID-19 …
to obtain preliminary biologic, physiologic, and clinical data in patients with COVID-19 …
The Controversy of Renin–Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection
AS Manolis, TA Manolis, AA Manolis… - Journal of …, 2020 - journals.lww.com
The ongoing COVID-19 pandemic has produced serious turmoil world-wide. Lung injury
causing acute respiratory distress syndrome seems to be a most dreaded complication …
causing acute respiratory distress syndrome seems to be a most dreaded complication …
Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019
MY Liu, B Zheng, Y Zhang, JP Li - Chronic Diseases and …, 2020 - mednexus.org
Coronavirus disease 2019 is a major threat to public health globally. Though its
pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has …
pathogenesis has not been fully elucidated, angiotensin-converting enzyme 2 (ACE2) has …
[HTML][HTML] High angiotensin-converting enzyme and low carboxypeptidase N serum activity correlate with disease severity in COVID-19 patients
PR Tepasse, R Vollenberg, N Steinebrey… - Journal of Personalized …, 2022 - mdpi.com
(1) Background: Angiotensin-converting enzyme 2 (ACE2) is a functional receptor of SARS-
CoV-2 and counter-balances ACE in the renin–angiotensin system (RAS). An imbalance of …
CoV-2 and counter-balances ACE in the renin–angiotensin system (RAS). An imbalance of …